Home›Oritavancin Diphosphate

Oritavancin Diphosphate

Also known as: Kimyrsa

Route: Intravenous

Check Oritavancin Diphosphate Interactions →

2 interactions on record

Oritavancin Diphosphate has 2 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Drugs Metabolized By Cyp2d6, Warfarin. Patients taking Oritavancin Diphosphate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 2
Moderate: 2

Moderate (2)

Oritavancin Diphosphate + Drugs Metabolized By Cyp2d6— Oritavancin is a weak CYP2C9 inhibitor; co-administration may increase or decrease concentrations of these drugs. Close …
Oritavancin Diphosphate + Warfarin— Oritavancin is a weak CYP2C9 inhibitor. Although a study showed no effect on S-warfarin pharmacokinetics, patients shoul…

Oritavancin Diphosphate + Drugs Metabolized By Cyp2d6🟡Moderate

Oritavancin is a weak CYP2C9 inhibitor; co-administration may increase or decrease concentrations of these drugs. Close monitoring for toxicity or lack of efficacy is recommended.

Oritavancin Diphosphate + Warfarin🟡Moderate

Oritavancin is a weak CYP2C9 inhibitor. Although a study showed no effect on S-warfarin pharmacokinetics, patients should be monitored closely for bleeding when concomitantly receiving oritavancin and warfarin.

Contraindications

4 CONTRAINDICATIONS Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after KIMYRSA administration. ( 4.1 , 5.1 ) Known hypersensitivity to oritavancin products. ( 4.2 , 5.2 ) 4.1 Intravenous Unfractionated Heparin Sodium Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after KIMYRSA administration because the activated partial thromboplastin time (aPTT) test results may remain falsely elevated for up to 120 hours (5 days) after KIMYRSA administration [see Warnings and Precautions (5.1) and Drug Interactions (7.2) ]. 4.2 Hypersensitivity KIMYRSA is contraindicated in patients with known hypersensitivity to oritavancin products.

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary There are no available data on KIMYRSA use in pregnant women to evaluate for a drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no effects on embryo-fetal development or survival were observed in pregnant rats or rabbits treated at the highest doses throughout organogenesis with intravenous oritavancin, at doses equivalent to 25% of the single clinical dose of 1,200 mg (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Reproduction studies performed in rats and rabbits have revealed no evidence of harm to the fetus due to oritavancin at the highest doses administered throughout organogenesis, 30 mg/kg/day (gestation days 6-17) and 15 mg/kg/day (gestation days 7-19), respectively. Those doses would be equivalent to a human dose of 300 mg, or 25% of the single clinical dose of 1,200 mg. Higher doses were not evaluated in nonclinical developmental and reproductive toxicology studies.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.